Avidity Biosciences, Inc. reported earnings results for the fourth quarter ended December 31, 2023. For the fourth quarter, the company reported net loss was USD 60.44 million compared to USD 50.47 million a year ago. Basic loss per share from continuing operations was USD 0.79 compared to USD 0.88 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
24.36 USD | +2.22% | +7.17% | +169.17% |
Apr. 04 | Avidity Biosciences Insider Sold Shares Worth $734,919, According to a Recent SEC Filing | MT |
Apr. 04 | Avidity Biosciences Insider Sold Shares Worth $542,214, According to a Recent SEC Filing | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+169.17% | 2.33B | |
-4.66% | 86.13B | |
+1.32% | 39.82B | |
-19.27% | 30.42B | |
+57.86% | 25.23B | |
-16.09% | 15.35B | |
-9.14% | 11.95B | |
-17.69% | 11.6B | |
-43.00% | 11.51B | |
+5.24% | 8.71B |
- Stock Market
- Equities
- RNA Stock
- News Avidity Biosciences, Inc.
- Avidity Biosciences, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023